Opiant Pharmaceuticals, Inc.
OPNTDelisted Mar 2, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001385508
Opiant Pharmaceuticals, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 37 institutions reported holding it in 13F filings for Q4 2022, worth $43.2M in total; no superinvestor held it.
Q4 2022 vs. Q3 2022
How the institutions holding Opiant Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 32 | 1 | 37 | +6 |
| Shares | 1.81M | 300 | 2.13M | +327.6K (+18.1%) |
| Value | $19.4M | $3.00K | $43.2M | +$23.8M (+122.9%) |
1 institution that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held Opiant Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Western Standard LLC | 424,080 | $8.60M | 7.57% |
| New York Life Investment Management LLC | 61,912 | $1.26M | 0.01% |
| CSS LLC | 61,349 | $1.24M | 0.08% |
| Ramius Advisors LLC | 55,298 | $1.12M | 1.08% |
| Yakira Capital Management, Inc. | 54,371 | $1.10M | 0.22% |
| Black Maple Capital Management LP | 48,548 | $984.6K | 1.58% |
| Ergoteles LLC | 43,200 | $876.1K | 0.03% |
| Schonfeld Strategic Advisors LLC | 42,300 | $857.8K | 0.01% |
| Gabelli Funds LLC | 37,119 | $752.8K | 0.01% |
| Gabelli & Co Investment Advisers, Inc. | 20,700 | $419.8K | 0.09% |
| Fifth Lane Capital, LP | 15,000 | $304.2K | 0.44% |
| Citadel Advisors LLC | 14,169 | $287.3K | 0.00% |
| Harvest Management LLC | 12,000 | $243.4K | 0.28% |
| Gamco Investors, Inc. Et Al | 10,000 | $202.8K | 0.00% |
| Bank of America Corp | 1,070 | $21.7K | 0.00% |
| Baldwin Brothers Inc | 300 | $6.08K | 0.00% |
| CoreCap Advisors, LLC | 266 | $5.39K | 0.00% |
Sold out (11)
Institutions that held Opiant Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| HealthInvest Partners AB | 210,000 | $2.26M |
| Stonepine Capital Management, LLC | 152,278 | $1.64M |
| Acadian Asset Management LLC | 126,978 | $1.36M |
| Essex Investment Management Co LLC | 47,169 | $507.0K |
| Perritt Capital Management Inc | 30,500 | $328.0K |
| Two Sigma Investments, LP | 21,730 | $234.0K |
| Bank of New York Mellon Corp | 17,796 | $191.0K |
| Mesirow Financial Investment Management, Inc. | 17,633 | $190.0K |
| Trexquant Investment LP | 13,219 | $142.0K |
| Susquehanna Fundamental Investments, LLC | 10,052 | $108.0K |
| National Bank of Canada | 100 | $1.00K |
Not filed for Q4 2022 yet (1)
Institutions that held Opiant Pharmaceuticals, Inc. at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| American Research & Management Co. | 300 | $3.00K |